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for the Treatment of Oropharyngeal Candidiasis in AIDS Patients
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This study was a non-comparative  multicenter clinical trial to evaluate the efficacy and
tolerability of itraconazole oral solution 200 mg/day (100 mg twice a day in the fasting state) for
the treatment of oropharyngeal candidiasis in AIDS patients. We included 50 patients who were
treated and followed for up to 3 weeks after ending therapy in the analysis. Mycological cures at
the end of therapy occurred in 20/50 patients (40%), but colonization by Candida sp. was recorded
in 42/50 (84%) by the end of follow-up. A high rate of clinical response was observed in 46/50
(92%), and the response was sustained for up to 21 days after stopping therapy in 24/46 patients
(52%). Clinical relapses were documented among 22 patients, but all causative fungal organisms
associated with a relapse were susceptible to itraconazole. There were many patients with
persistence or recurrence of Candida, but without mucositis. Relapse of Candida mucositis was
significantly related to low levels of CD4 lymphocytes exhibited by symptomatic patients. The drug
was well tolerated by all but 1 patient.
We conclude that itraconazole oral solution (100 mg bid for 7-14 days) is a well tolerated and
effective treatment for suppressing the symptoms of oropharyngeal candidiasis in AIDS patients.
Patients with severe immunosuppression may relapse and require frequent cycles of treatment or
longterm suppressive therapy.
Key Words: AIDS, candidiasis, itraconazole.
Received on 10 January 2001; revised  11 April 2001.
Address for correspondence: Dr.  Arnaldo Lopes Colombo, MD.
Disciplina de Doenças Infecciosas e Parasitárias, Escola Paulista
de Medicina-UNIFESP- Rua Botucatu, 740, Zip Code: 04023-062
- São Paulo-SP, Brazil.  E-mail: lemidipa@vento.com.br This study
was made possible by financial support and pharmaceuticals
from Janssen Research  Foundation
The Brazilian Journal of Infectious Diseases 2001;5(2):60-66
© 2001 by The Brazilian Journal of Infectious Diseases and
Contexto Publishing. All rights reserved.
1413-8670
The prognosis of individuals infected with HIV
has changed considerably since the introduction of
antiretroviral drug combinations, including protease
inhibitors and non-nucleoside analogue reverse
transcriptase inhibitors. Several authors have
reported reductions in morbidity and mortality
among AIDS patients under antiretroviral therapy.
However, continued increases in HIV infection have
been documented in under developed countries,
mainly from sub-Saharan Africa,  Southeast Asia
and some Latin American countries. The public
health systems in these region are not able to
provide antiretroviral drugs to HIV-infected
patients. As a consequence, it is expected that
opportunistic infections associated with AIDS
patients will remain a major problem in these parts
of the world [1].
Oropharyngeal candidiasis (thrush) is the most
common opportunistic infection in AIDS patients and
its occurrence increases as CD4 counts decrease [2].
Topical antifungal therapy may be used to treat mild
episodes of thrush [3,4] but systemic antifungal
therapy is  needed for the treatment of extensive and
recurrent episodes of thrush [5-7]. Itraconazole has
demonstrated a broad spectrum of antifungal activity
in vitro, including a wide range of Candida spp [8-
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10]. However, the benefit of itraconazole treatment
of Candida mucosal infections in AIDS patients may
be limited by the low bioavailability of the capsule
formulation [11].
To overcome some of the limitations associated
with capsule formulation, a soluble formulation of
itraconazole in hydroxypropyl-b-cyclodextrin was
developed [12]. This has a better systemic absorption
as well as topical action [13,14]. Itraconazole oral
solution (IOS) has been successfully used to treat
thrush and Candida esophagitis in AIDS patients [15-
21]. We present the clinical and mycological results
of the first non-comparative clinical trial performed in
Brazil to evaluate the efficacy and tolerability of
itraconazole oral solution for treatment of adult AIDS
patients with thrush.
Materials and Methods
Male and female HIV-infected patients over 18
years of age were eligible for the study if they met the
following criteria: a clinical picture of
pseudomembranous oropharyngeal candidiasis and
findings on direct microscopic examination (KOH
smear) consistent with Candida spp, further confirmed
by a positive fungal culture.
Patients were excluded from study participation for
any of the following reasons: a history of topical or
systemic antifungal therapy  within 7 or 14 days,
respectively, of entering the study; presence of
symptoms suggestive of esophageal candidiasis; a
history of hepatic failure; life expectancy of less than 1
month; pregnancy or women of child-bearing potential
not practicing adequate birth control, and  lactating
females; patients requiring concomitant therapy with
drugs that could interact with itraconazole (H2-receptor
blockers, antiacids, rifampin, rifabutin, phenobarbital,
phenytoin, carbamazepine, terfenadine and astemizole).
All volunteers signed an informed consent prior to
inclusion in the study.
This study was a non-comparative  multicenter
clinical trial performed to evaluate the efficacy and
tolerability of itraconazole oral solution (IOS) 200 mg/
day (100 mg twice a day) for 7 or 14 consecutive days.
IOS was given in the fasting state. Patients were instructed
to swish the oral cavity with 10 mL aliquots of solution
(100 mg/10 mL) for several seconds and then swallow.
Following the initial visit on entering the study, visits
were scheduled on days 7, 14, and 28. Clinical and
epidemiological data for all patients, as well as the
laboratory results (complete blood count, CD4 count
and biochemical tests) were recorded. At the first visit,
the severity of lesions was evaluated as localized (single
lesion) or extensive (multiple or confluent lesions). The
efficacy of the antifungal therapy was assessed based
on resolution of signs and symptoms noted at the first
visit and by mycological investigation. The clinical
response was rated as cured (clearance of all signs
and symptoms), improved (minimal signs and symptoms
compared with the first visit) or failed (persistence or
worsening of signs and symptoms). For mycological
investigation, oral samples were obtained by swabbing
the oral cavities of all patients during all scheduled visits,
and the biologic material was cultured.
The primary efficacy parameter was the initial clinical
response. Patients rate as cured or improved after 7
or 14 days of therapy were considered to have a
successful outcome and were eligible for the follow-up
phase. Recurrence was defined as a return of signs
and symptoms in a patient with a previously successful
clinical response.
A mycological cure was defined as a negative culture
of the oral sample obtained at the end of therapy, and
re-colonization as a positive culture obtained following
a negative culture, regardless of the presence or
absence of signs and symptoms.
All cultures were performed on plates of
Sabouraud-dextrose agar with chloramphenicol and
incubated at 30°C for 7 days. Positive cultures were
sent to the Special Micology Laboratory of the Division
of Infectious Diseases and Parasitology at the Federal
University of São Paulo, for further analysis and
determination of the antifungal susceptibility profile. The
identification of the yeast isolates was based on
micromorphology characters of the colonies and the
biochemical profile evaluated with the aid of API
galleries [22]. The fungal isolates obtained at the first
visit, at the end of therapy, and at any recurrent episodes
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were submitted to antifungal susceptibility tests
performed according to the NCCLS standard
procedures [23].
For safety evaluation, a medical history, physical
examination and laboratory tests of blood samples
(hemogram, hepatic and renal functions) were collected
before therapy and at the end of therapy.
Results
Patients
Fifty patients from 5 centers were included in the
present study. Baseline and demographic characteristics
of all patients are presented on Table 1.  The low mean
CD4 count and the high incidence of concomitant
diseases exhibited by most of the patients confirmed
the advanced status of AIDS among this population.
Candida albicans accounted for 100% of the yeasts
obtained at the baseline cultures and all isolates were
susceptible to the azoles tested (see data in Table 1).
Efficacy analysis
The clinical and mycological assessments were
performed for up to 3 weeks following treatment
withdrawal.  Forty six of the 50 treated patients (92%)
were considered clinically cured 14 days after
beginning treatment. Forty-three of these patients
were free of lesions after 7 days of treatment.  There
were 4 failures.
During the follow-up period, we identified 22
clinical recurrences (48%).  Of note, 16 of the 22
patients had a previous positive culture before the
clinical evidence of thrush at the third week visit.
Twenty four patients (52%) remained lesion-free at the
end of the follow-up period.
The mycological cure rate was 20/50 (40%). The
colonization rate among the initial responders was 91%
(42/46 patients) at the third visit, but only 22 patients
developed oral thrush at that time.
At the end of the follow-up period, the species
distribution of the 42 colonized patients was: C.
albicans (39), C. krusei (1), C. tropicalis (1) and C.
inconspicua (1).  All those clinical isolates were still
susceptible to itraconazole (MIC range 0.015 mg/mL
to 0.25 mg/mL), but  1 isolate was resistant to
fluconazole (C. krusei). There were significantly more
recurrences in the group of patients with CD4 counts <
50 mm3, than in those with CD4 counts > 50 mm3
(Figure 1). There was no relationship between
recurrences and high values of itraconazole or
fluconazole MICs of the isolated yeasts.
Safety analysis
Safety evaluations in all 50 patients revealed only 1
patient with significant adverse events related to the
study drug (epigastric pain and flatulence) but the
treatment was continued. No significant changes were
observed in clinical or laboratory evaluations of the
enrolled patients.
Discussion
Fluconazole is a predictably absorbed, well-
tolerated, safe and very useful drug for the treatment
of mucosal candidiasis [24]. However, fluconazole
refractory oropharyngeal candidiasis has emerged as
an important illness among advanced AIDS patients.
Morbidity related to this condition may cause significant
difficulty for adequate nutritional intake as well as for
swallowing oral medications. Incidence of fluconazole
refractory mucosal candidiasis is reported from 4% to
7% of such patients [25]. The rates of Candida spp
ketoconazole and itraconazole resistance have been
reported less frequently, but the clinical use of both
azoles is less frequent for treatment of candidiasis due
to their limited bioavailability.
The occurrence of mucosal candidiasis refractory
to azoles may be a result of several causes including
poor compliance with the prescribed antifungal drug
treatment protocol, drug interactions causing low
azole plasma levels, poor absorption of the drug,
significantly impaired immune response, or selection
of isolates with primary or secondary resistance to
azoles [26]. Consequently, the development of a
new formulation of IOS exhibiting greater
IOS for the Treatment of Oral Candidiasis
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Table 1. Demographic, clinical and laboratory baseline data of 50 patients with AIDS and oral candidiasis
Figure 1. Correlation between CD4 cells count and clinical outcome of patients with thrush treated with itraconazole
oral solution (p < 0.0004, Fischer)
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Characteristics
Gender (Female / Male ) 18/32
Age (years) (median - range) 34.5 (21 - 49 )
Weight (median - range - kg) 53.5 (30 - 92)
CD4  count/mm3
mean ± SD 37.9 ± 44.3
median (range) 26 (3 - 210)
Concomitant diseases   n %) 36 (72%)
Extension of oral thrush
Localized  n (%) 16 (32%)
Extended  n (%) 34 (68%)
Baseline oropharyngeal culture
C. albicans    n (%) 50 (100%)
 Pretreatment  MIC (mg/mL) Itraconazole Fluconazole
MIC 50%     (median) 0.06 0.25
MIC             (range) 0.015-0.07 0.125-2.0
Percentage of patients that were lesion free 14 and 28 days after beginning of treatment
95%
80%
23%
38%
91%
88%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Day 0 Day 14 Day 28
CD 4 > 50 (n=20)
CD 4 < 50 (n=22)
w/o data (n=8)
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bioavailability than itraconazole capsules may have
beneficial effects in the clinical management of azole
refractory mucosal candidiasis.
In the present study, IOS was successfully used to
treat extensive oral candidiasis lesions among AIDS
patients in advanced stages of disease. We obtained a
high rate of clinical response (92%) that was sustained
for up to 21 days after ending therapy for 24 patients.
All cases of thrush were caused by C. albicans isolates
susceptible to fluconazole and itraconazole. The drug
was well tolerated by all but 1 patient who developed
epigastric pain and flatulence.
Clinical relapses were documented among 22
patients, but all causative fungal organisms were
susceptible to itraconazole.  Patient compliance with
the treatment protocol was unremarkable according
to the information collected during the clinical visits.
Unfortunately, we were not able to measure the serum
levels of itraconazole among the treated patients.
Considering the data we collected, relapse of Candida
mucositis was clearly related to the depletion in the
levels of CD4 lymphocytes. These results are in
accordance with data published by other investigators
who have also reported a higher incidence of recurrent
disease among patients with low CD4 levels.
The itraconazole solution formulation is prepared
with a hydroxypropyl-b-cyclodextrin vehicle and
absorption is optimal in the fasting state [27]. The
bioavailability of the solution has been shown to
be 24% to 60% greater than that of the capsules
[28]. Better absorption may, in part, account for
the improved efficacy of the solution in refractory
OPC patients [17]. However, clinical responses
were observed in several patients despite steady
state itraconazole levels being well below the MIC
for the Candida spp. isolates [18]. This suggests
an important topical effect of the solution. Further
support for this observation is provided by the
finding of high salivary levels of itraconazole that
were sustained up to 4 h after dosing during
treatment [14].
Reynes studied the pharmacokinetics of IOS
showing that its bioavailability is not modified by the
stage of HIV infection. Effective concentrations in
plasma (> 250 ng/ml) are achieved at day 4.
Concentrations > 250 ng/ml are present in saliva 4 hours
after intake and probably contribute to the rapid clinical
response [14].
The clinical efficacy and safety of the new
formulation of itraconazole has been studied in
several controlled, randomized, open label trials in
HIV/AIDS patients with oral trush and esophagitis.
Preliminary clinical studies in AIDS patients with
severe oral candidiasis have shown that IOS (100
mg bid) produced a 100% clinical cure rate  [15]
and is more effective than topical therapy with
clotrimazole [16].
Graybill and colleagues compared the efficacy
and tolerability of the IOS (100 mg bid) for 7 or
14 days, with 14 days of fluconazole tablet for the
treatment of oral candidiasis in HIV/AIDS patients.
Both 7 days and 14 days of IOS were equivalent
to 14 days of fluconazole. The clinical response
was 97% and 87% for the 14 day regimen of
itraconazole and fluconazole, respectively, and
86% in the itraconazole 7 day group. In this study,
mycological cure was 88% for itraconazole (14
days), and 77% for fluconazole. Nearly half of all
patients relapsed within 30 days of terminating of
treatment [19].
Phillips and colleagues evaluated the efficacy of
IOS in 36 cases of fluconazole refractory
oropharyngeal candidiasis. Clinical response was
observed in 65% of  evaluated cases. The median
MIC of  fluconazole was 64 mg/mL, compared to
0.5 mg/mL for control cases. The median
itraconazole MIC was 1.25 mg/mL compared to
0.078 mg/mL for controls [18].
Wilcox showed a clinical response rate of 94% in
patients with esophageal candidiasis treated with IOS
[20]. Moskovitz showed that clinical and endoscopic
efficacy between IOS and fluconazole for the treatment
of esophageal candidiasis were equivalent [21].
In conclusion, itraconazole oral solution (100 mg
bid for 7 or 14 days) is a well tolerated and effective
treatment in suppressing the symptoms of
oropharyngeal candidiasis in AIDS patients. Patients
with severe immunosuppression may develop relapses
IOS for the Treatment of Oral Candidiasis
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and require frequent cycles of treatment or ongoing
suppressive  therapy. Itraconazole offers an important
alternative to other azoles currently in clinical use, with
superior efficacy of IOS over capsules due to enhanced
bioavailability and additional topical activity.
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